Showing posts with label FDA. Show all posts
Showing posts with label FDA. Show all posts

Friday, December 20, 2013

#Vedolizumab - Favorable Among FDA for Ulcerative #Colitis & #Crohns

Good News!!  The FDA supports the approval of Vedolizumab for the treatment of Crohn's disease and ulcerative colitis.  The treatment looks extremely promising with a safety profile to be recognized.  
Hey, If I would consider the treatment, it has to have minimal/low risks in regard to serious side effects that a lot of biologics have.  Vedolizumab is looking good in the safety department.
The FDA will make the decision to either approve or deny treatment for use among ulcerative colitis (UC) patients by Feb. 18.  The decision for Crohn’s disease (CD) patients will be several months later around June. 




SILVER SPRING, Md. -- Most members of an FDA advisory committee support approval of the investigational biologic agent vedolizumab for Crohn's disease, as well as supporting an additional indication for ulcerative colitis.


In the closest vote of the Gastrointestinal Drugs and Drug Safety and Risk Management joint advisory committee meeting, the members voted 12-9 in favor of recommending approval of the drug for its Crohn's indication as an induction therapy, while the panel voted 20-0, with one abstention, to greenlight the drug as a maintenance therapy for the condition.
"While the data for Crohn's disease don't appear quite as strong, there does appear to be some efficacy and particularly the 10-week data were compelling," noted panelist Linda Feagins, MD, of the University of Texas Southwestern Medical Center in Dallas. She added that "the need for other treatment for Crohn's disease is great and we see that every day treating our patients, and I feel that doing further trials and holding this for patients will increase costs and delay drug availability."
Because the meeting was delayed by 2 hours due to inclement weather, the panel announced early in its Monday session that it would skip a formal vote on the ulcerative colitis indication, citing overwhelming evidence in its favor.
Vedolizumab's manufacturer, Takeda Pharmaceuticals, submitted the drug for approval for the Crohn's disease and ulcerative colitis patient population who had moderate to severely active disease and who were inadequately treated with, did not respond to, or were intolerant of convention therapy or a tumor necrosis factor-alpha antagonist.
Phase III trial data showed the drug was effective in ulcerative colitis patients, but only one of two trials showed drug efficacy at 6 weeks for Crohn's disease. However, data presented during the panel meeting out to 52 weeks of treatment showed significant improvements in remission rates among those who received drug treatment for 4 and 8 weeks.


Another issued raised prior to the panel discussion were concerns over risks for progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal demyelinating condition that can occur in patients receiving natalizumab (Tysabri) and other immunosuppressive medications and who are infected with JC virus.
However, in the only unanimous vote of the session, all 21 panelists voted Yes that Takeda had sufficiently accounted for the risk of PML to support approval; Takeda said that although no cases had occurred during phase III studies, the company would still conduct post-market research and include a warning in its packaging. The panel routinely supported its vote with praise for the risk mitigation strategy and post-market research.
Another vote concerned whether concomitantly administered immunosuppressants should be limited to a specific duration. The panel voted 19-1, with one abstention, against such a limit.
For each condition, the panel voted on whether benefits outweighed risks to support approval of the drug in patients who failed steroid, immunosuppressive, or TNF-alpha antagonists; immunosuppressants or TNF-alpha antagonists; or neither. The vote for ulcerative colitis favored treatment for all conditions, with 14 voting for the first option, seven voting for the second, and none voting for the third. Similarly for Crohn's disease, 14 favored the first option, six favored the second, and one panelist favored neither.
Regarding the vote for the ulcerative colitis indication, committee member Elaine Morrato, DrPH, of the Colorado School of Public Health in Aurora, voted for the least restrictive option, but noted that "the products should be effective, but I worry that a specific requirement for failure of immunosuppressant or anti-TNF would be overly burdensome when you're translating this into clinical practice," adding that she "would rather have those discussions left with the patient and the provider."
Those favoring the middle option preferred a bottom-up approach while waiting for additional data on which patient populations would be best served by the drug with the least risk.
The agency is not required to follow the advice of its advisory committees, though it often does.

Friday, June 28, 2013

New Law -> Regulates Antibiotic Use On Farm Animals

The FDA should have taken action a long time ago with regulating the use of antibiotics for farm animals, especially the healthy animals that don't need them.  Of course, everytime we eat non-organic meat (sometimes I even wonder about the quality of "organic" meat in the US) we are pretty much swallowing antibiotics and most people don't even recognize this or think about it... OR they just don't care.  As the article says:  
"The over-use of these antibiotics contributes to the development of so-called ’superbugs,’ or infections that cannot be treated with existing medicines." 
I recently read that C-Diff has now developed a strain being a superbug.  When I read that 300 people a day die from C-diff... A DAY, my jaw dropped.  I thought the words after 300 would be something more like "people per month".  That sounds about right in my opinion, but things have gotten out of control in this country.  The use of drugs for everything and the medical field's lack of knowledge of NATURAL, more healthy ways of eradicating a pathogen/illness is now biting us in the ass.    
"A recent study published in the medical journal, Clinical Infectious Diseases, found that nearly 50 per cent of grocery store meat was contaminated with antibiotic resistant pathogens, according to the Senator. Approximately 25 per cent of this meat was contaminated with pathogens that were resistant to three or more type of antibiotics." 
Mmmmm yummy!  Makes you want to have a nice steak huh?! Yeah right... ORGANIC ONLY.  The standards that certified organic follow should be the normal standards for all farms and all the food that is allowed into the grocery store for human consumption.  That 50% of meat that is full of pathogens is not even fit for an animal to consume and people are eating it everyday.      Y  U  C  K!    







New Law Introduced to Safeguard Use of Antibiotics in Agriculture

28 June 2013
US - Senator Dianne Feinstein (D-California) has introduced legislation to combat antibiotic resistant superbugs that develop when antibiotics are misused in animal agriculture.
The Preventing Antibiotic Resistance Act of 2013 directs the Food and Drug Administration to prohibit the use of human antibiotics in the feed and water of healthy farm animals if they jeopardize human health.
The bill requires drug companies and agriculture producers to demonstrate that antibiotics are used to treat clinically diagnosable diseases - not just to fatten livestock. The over-use of these antibiotics contributes to the development of so-called ’superbugs,’ or infections that cannot be treated with existing medicines.
“Antibiotics are the closest thing to a ‘silver bullet’ in human medicine given their ability to wipe out a wide variety of bacterial infections, but we are in danger of losing this weapon in the fight against infectious diseases,” said Senator Feinstein. “When antibiotics are fed in low doses to animals, only the strongest, most resistant bacteria are left behind to reproduce. By the time these resistant pathogens make their way from the animals into our communities, the infections can be costly to treat or untreatable all together.”
A recent study published in the medical journal, Clinical Infectious Diseases, found that nearly 50 per cent of grocery store meat was contaminated with antibiotic resistant pathogens, according to the Senator. Approximately 25 per cent of this meat was contaminated with pathogens that were resistant to three or more type of antibiotics.
“The irresponsible use of antibiotics is dangerous, and tens of thousands of people in the US die each year from antibiotic resistant infections,” Senator Feinstein added. “We must preserve the efficacy of these life-saving drugs by carefully restricting their overuse in our agriculture products.”
The Preventing Antibiotic Resistance Act of 2013:
  • directs the Food and Drug Administration to prohibit the use of antibiotics in ways that accelerate antibiotic resistance
  • requires drug companies and producers to demonstrate they are using antibiotics to treat clinically diagnosable diseases—not just to fatten their livestock
  • applies restrictions to only the limited number of antibiotics that are critical to human health. Any drug not used in human medicine is left untouched by this legislation, and
  • preserves the ability of farmers to use all available antibiotics to treat sick animals. If a veterinarian identifies a sick animal, or a herd of animals that are likely to become sick, there are no restrictions on what drugs can be used.
More than 375 public, consumer and environmental health groups, including the American Medical Association, the American Public Health Association, and the Infectious Diseases Society of America, support the legislation.
Senators Susan Collins (R-Maine), Jack Reed (D-Rhode Island), Maria Cantwell (D-Washington), Kirsten Gillibrand (D-New York) and Barbara Boxer (D-California) are co-sponsors of the legislation.
ThePigSite News Desk

Monday, November 12, 2012

Soligenix- SGX203 was FDA "Fast Track" Designation to Treat Pediatric Crohn's Disease

Announcement of the FDA approval of SGX203 for children with mild to moderate Crohn's Disease.


Soligenix SGX203 programme to treat paediatric Crohn’s disease receives US FDA fast track designation

Princeton, New Jersey
Monday, November 12, 2012, 17:30 Hrs  [IST]
The US Food and Drug Administration (FDA) has granted “Fast Track” designation to Soligenix programme for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the induction treatment of mild-to-moderate paediatric Crohn’s disease.

Soligenix has also previously received Orphan Drug Designation from the FDA for oral BDP as a treatment for paediatric Crohn’s Disease.

Fast track is a designation that the FDA reserves for a drug intended to treat a serious or life- threatening condition and one that demonstrates the potential to address an unmet medical need for the condition. Fast track designation is designed to facilitate the development and expedite the review of new drugs. For instance, should events warrant, Soligenix will be eligible to submit a new drug application (NDA) for SGX203 on a rolling basis, permitting the FDA to review sections of the NDA prior to receiving the complete submission.  Additionally, NDAs for fast track development programs ordinarily will be eligible for priority review, which implies an abbreviated review time of six months.

“There are no FDA approved corticosteroid therapies for the induction treatment of Crohn’s disease in the paediatric population,” stated Christopher J Schaber, president & chief executive officer of Soligenix. “The FDA's action in granting fast track designation is an indication of SGX203's potential to address this debilitating, unmet medical need.  We look forward to working closely with the FDA to potentially expedite the development and NDA review process.”

Crohn's disease is an ongoing disorder that causes inflammation of the gastrointestinal (GI) tract. Crohn's disease can affect any area of the GI tract, from the mouth to the anus, but it most commonly affects the lower part of the small intestine, called the ileum. The swelling caused by the disease extends deep into the lining of the affected organ. The swelling can induce pain and can make the intestines empty frequently, resulting in diarrhea. Because the symptoms of Crohn's disease are similar to other intestinal disorders, such as irritable bowel syndrome and ulcerative colitis, it can be difficult to diagnose. People of Ashkenazy Jewish heritage have an increased risk of developing Crohn's disease.

Crohn's disease can appear at any age, but it is most often diagnosed in adults in their 20s and 30s. However, approximately 30% of people with Crohn's disease develop symptoms before 20 years of age. Paediatric Crohn's disease is a subpopulation of approximately 80,000 patients 0-19 years of age in the United States.  Crohn’s disease tends to be both severe and extensive in the pediatric population and a relatively high proportion (25-40%) of pediatric Crohn’s patients have involvement of their upper gastrointestinal tract.

SGX203 contains BDP, a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the United States and worldwide since the early 1970s as the active pharmaceutical ingredient in inhalation products for the treatment of patients with allergic rhinitis and asthma. SGX203 is a two tablet delivery system (i.e., immediate and delayed release) of BDP specifically designed for oral use that allows for delivery of BDP throughout the small bowel and the colon. The FDA has previously awarded SGX203 Orphan Drug Designation for the treatment of pediatric Crohn's disease.

Soligenix is a development stage biopharmaceutical company developing products to treat serious gastrointestinal diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics.

How it works - SGX203 is specifically formulated for oral administration as a single product consisting of two tablets. One tablet releases BDP in the upper gastrointestinal (GI) tract and the other tablet releases BDP in the lower GI tract. 

We will initiate a SGX203 development program for pediatric Crohn’s disease program in 2012. The objective of developing SGX203 for pediatric Crohn’s is to make available a corticosteroid option with less toxicity than the current standard therapy prednisone. 

Soligenix SGX203 programme to treat paediatric Crohn’s disease receives US FDA fast track designation:

'via Blog this'

A MUST READ! Article Focused on False Information Discrediting Natural Health Supplements

Here is a MUST READ that I received in my e-mail. This was originally published several years ago however, is extremely relevant today! It just goes to show us that the distorted reports against natural supplements/vitamins has persisted year after year, right up to 2012.   
Really, this information is exactly inline with the things that I believe and have mentioned to people at one time or another, especially regarding the absolute fact that the pharmaceutical industry and the current healthcare system is CORRUPT! The reason I use the word "corrupt" is because the focus on making drugs by most pharm companies (most...not all drug companies. There's some companies that are not consumed with greed and have a goal of getting people healthier.. They are few, but exist) is not to cure you, but to manage symptoms.  Do you realize how much money would be lost if they cured illnesses?   Exactly...BILLIONS!

It's vital to know what's going on within these industries....  
1) if you take any prescribed medication. (It's your responsibility to do your part before committing to treatment) 
2) if a friend or family member is prescribed medication. 
3) if you care at all about your life & are caught up in a vicious cycle of getting better then ill (neither one of them last very long).  Basically, if you are not getting better & you always feel "off" and not quite yourself. You're in a standstill.  
4) if you know there's something not right within the medical industry, but you can't really pinpoint exactly what it is. You are aware that there are major flaws and want to learn more and educate yourself.
5)If you want to blow the whistle on this sad situation and want to be a voice to spread truth.
6) If you are driven and feel a strong conviction to EXPOSE what's going on in our healthcare system today and want to see a positive change.
7) If you want to have the knowledge about what's happening in our nation and around the world regarding an area that WILL one day impact your life (everyone will be effected by the condition of these industries at one point in your lifetime. 

Health fails us... it's inevitable that as we age things in our body breakdown, need special attention & care, require repair. 
   
Newsletter from Jini Patel Thompson. Her website info is at the end of this article.  Visit her site for more articles.



HOW PHARMACEUTICALS USE "EXPERTS" TO DISCREDIT NATURAL MEDICINE 

You may have noticed this already: Whenever a natural supplement or herbal medicine becomes well-known and widely used, with lots of evidence piling up for its efficacy - there will then be a slew of media releases in newspapers, magazines, and tv news reports, discrediting that natural medicine. Or, the FDA will ban the substance based on trumped-up charges of user damage. This is exactly what happened with one of the best wound healers I've ever found called Comfrey. The FDA found one person who they claimed died of Comfrey use (the person had long-term, extensive medical problems, was very sick already and then began drinking ridiculous amounts of Comfrey tea) and based on that one incidence, they banned Comfrey use. Of course, no mention or comparison to the 7000 people who die EVERY YEAR in the US from Aspirin use! Then they set upon other bestsellers like Ma Huang (ephedra), St. John's Wort, and Vitamin E, the list goes on and on.

Well recently I received this article from the Alliance for Natural Health (a European organization) that does an excellent job of detailing exactly HOW pharmaceutical-backed interests use " scientific " experts" to compile evidence against natural remedies.

You need to know this information to help you understand how the medical and pharmaceutical industries are very clearly focused on keeping you on your drugs. It's all about money. They don't want anyone getting better, because then they lose massive amounts of money. Read on so you can educate yourself and become savvy about this insidious battle for your healthcare dollars...

________________________________________________________________

ANH Press Release-19 April 2006

META-ANALYSIS: a new tool to discredit natural health supplements?
By Dr Robert Verkerk, Executive & Scientific Director, Alliance for Natural Health

On 24 March 2006, The British Medical Journal' published a meta-analysis (a study of other studies) on omega-3 fatty acids [1] that prompted headlines around the world to the effect that "fish oils don't work". This is not the first time a meta-analysis has triggered headlines that discredit natural health supplements.


THE VITAMIN E META-ANALYSIS OF 2004
________________________________________________________________


In November 2004, Dr Edgar Miller and colleagues published electronically in the Annals of Internal Medicine a meta-analysis [2] that provided headlines as bizarre as "High dose vitamin E death warning" (this headline was run by none other than the BBC on 11 November 2004). The meta-analysis appeared to be pitched to tarnish the reputation of vitamin E, a nutrient in which many are known to be deficient. Among many of its problems, the study failed to show how healthy people would respond to supplemental intakes of vitamin E and it only included studies on synthetic vitamin E (dl-alpha-tocopherol). It therefore omitted any consideration of the effects of the seven other related compounds that make-up full spectrum, natural vitamin E, as found in vegetable oils. Interestingly, the body's absorption of the most important dietary form (gamma-tocopherol) is hindered by high doses of synthetic vitamin E, and this could have explained the negative results found by Miller et al.

The overall conclusion that high-dose vitamin E causes increased mortality could also have been a statistical artefact, with no biological relevance. Since the study assessed all-cause mortality, and not just cardiovascular mortality, other factors could easily have contributed to the greater death rate in the higher dose vitamin E group found when trials were pooled. It should be noted that the increased death rate was marginal; just 63 additional deaths per 10,000 persons, compared with the control group. Given that the confidence interval ranged from 6 to 119, this increased death rate cannot be said to be statistically significant.

Prior to this meta-analysis on vitamin E, market research data from Frost & Sullivan showed that vitamin E was the second most consumed single vitamin supplement, after vitamin C, in Europe. High-dose Vitamin E could have easily been perceived by Big Pharma as a threat to its huge cardiovascular drug market, comprised of statins, beta-blockers and ACE-inhibitors. In fact, Big Pharma had demonstrated such a strong interest in vitamins that it established an illegal cartel to control the markets and prices of a range of key vitamins, including vitamin E. Fortunately for the consumer, the conspiracy was eventually exposed and pharma companies like BASF and Hoffman-La Roche, as well as some of their top executives, got busted. Fines imposed by the US Justice Department in the US (May 1999) and, separately, by the European Commission (November 2001), which amounted to hundreds of millions of dollars in the US and similar amounts in Europe, are still among the largest ever imposed following an anti-trust investigation. Undeterred by this prosecution, Big Pharma continued its campaign against supplements, with the meta-analysis on vitamin E appearing in the peer-reviewed journal Annals of Internal Medicine just three years later.


THE ANTIOXIDANT VITAMIN META-ANALYSIS OF 2003
________________________________________________________________


A year earlier, in June 2003, another meta-analysis appeared. This one was published in the prestigious medical journal, the Lancet, by Dr Marc Penn and colleagues from the Cleveland Clinic [3]. These authors asserted that beta-carotene, vitamin A and other antioxidant vitamins such as vitamin E, were harmful. These authors re-iterated yet again negative results from a very small clutch of studies on synthetic vitamins like synthetic beta-carotene and vitamin E, which were once more administered to diseased or high risk subjects, and often for inadequate periods of time.

Following the publication of the meta-analysis, the lead author was quoted in the media saying that people should stop taking supplements containing vitamins A, beta-carotene and E. These conclusions, some of which were carried over into the vitamin E meta-analysis the following year, are profound misinterpretations of the existing evidence base, and most certainly cannot be applied to the role of these vitamins in reducing risks of chronic diseases such as cancer and cardiovascular disease in healthy people. Nor can these conclusions be applied to supplements containing natural forms of these vitamins.

Back to the omega-3 meta-analysis of 2006

Last month's attack on fish oils prompted by the meta-analysis by Dr Lee Hooper and his colleagues, as published in the BMJ, must surely be seen in the same light as the two meta-analyses discussed above. Put bluntly, the meta-analysis appears to be, once more, a vehicle to generate negative headlines. In fairness, even the authors have now conceded that they were "misquoted in much of the press." [4]

The scientific evidence for long chain omega-3 benefits on lowering triglycerides and other risk factors in heart disease, as well as clear, beneficial immune system modulation and behavioural effects, have been regarded by scientists, doctors and health authorities around the world as conclusive. This evidence has formed the basis of recommendations to consume oily fish or fish oil supplements by many governments. Where governments have stipulated a limit on the maximum amount to be consumed, such as no more than three portions of oily fish weekly, this has served mainly as a means to limit intake of heavy metals like mercury, or other contaminants such as dioxins or PCBs common in most wild fish [5]. Peculiarly, governments have appeared shy of recommending high-quality fish oil supplements which are often guaranteed as being free of any significant levels of these contaminants. This is particularly relevant given that specific batches of several low cost, mass market fish oil product lines have recently had to be withdrawn from the UK market owing to dioxin contamination (e.g. several Seven Seas [owned by pharma giant Merck] fish oil product batches were withdrawn on 14th March 2006, and on 11th March 2006 high street pharmacy chain Boots withdrew two batches of its own brand fish oil product).

In closely scrutinising Hooper et al''s paper, one thing becomes apparent: the findings are not nearly as damning as those suggested by the negative headlines on omega-3 fats that rebounded around the world for over a week. In fact, to the contrary; when it comes to the studies with fish oils only, the news appears just as rosy as we had all thought.

Ten out of 12 randomised control trials considered in the meta-analysis that assessed these oils in relation to total mortality point to positive findings. The same can be said for all three cohort studies considered by the meta-analysis authors. That's thirteen out of fifteen studies showing favourable results for higher intakes of omega-3 fats. The remaining two studies have been presented as showing very slightly negative findings, but in both cases the studies deal with existing disease states, either angina or coronary artery bypass grafts. The negative effects, in both cases, are so small that they could be regarded as having little or no biological relevance (in one study there was half a percent greater mortality in the treatment compared with control, while in the other there was a little over a 2% difference). The meta-analysis authors themselves considered both studies as being of medium to high risk of bias, which might in itself explain or at least contribute to such variations.

So, while the world was assaulted with headlines such as "The benefits of fish and linseed oils as elixir of life are another health myth" (this example being courtesy of The Times newspaper), we could have just as easily, and much more correctly, read headlines along the lines of: "New meta-analysis reinforces the health benefits of fish oils." But perhaps fewer newspapers would have sold on 24 and 25 March 2006.

Smearing the data with margarine

Even when Hooper and co-workers included studies with plant-derived, short chain omega-3 fats, such as those found in certain vegetable oils (e.g. flax) including margarines, the overall trend still pointed to reduced mortality for those consuming higher intake levels of all forms of omega-3.

The study that was presented as having the most pronounced apparent negative effect was one published in 2002 by Groningen University's Dr Wanda Bemelmans and colleagues [6]. The study, known as the MARGARIN trial, investigated the effect on heart disease risk of a Unilever margarine enriched with alpha-linolenic acid (ALA), an important short-chain omega-3 found to be rich in Mediterranean diets, well known for their health promoting properties. The study also aimed to assess the effect of group education on the benefits associated with consuming a typical Mediterranean diet. Importantly, the subjects in the study all had multiple cardiovascular risk factors; nearly half were smokers and took anti-hypertensive drugs, while over 40% had family histories of cardiovascular risk.

Bemelmans and colleagues' own findings, in contrast to their interpretation of these findings in the Hooper et al meta-analysis, are overwhelmingly positive. They demonstrate clearly the beneficial effects of ALA-enriched margarine on reducing heart disease risk. The study also shows that group education led to healthier diets, with increased consumption of fish, and consequently lower heart disease risk factors. These findings are actually fully in line with another major study, the Lyons Diet Heart Study, published in 1994 in the Lancet, which actually provided the inspiration for Bemelmans and colleagues' MARGARIN trial.

So, how was this study distorted to give the impression that omega-3 fats might be bad for you? This is down to the very small number of deaths recorded, which could just as easily be a function of chance rather than any treatment effect. The study included only four deaths out of 266 subjects in total. The omega-3 meta-analysis authors managed to blacken this study because 3 out of 4 of these deaths (again from all-causes, not just cardiovascular disease) occurred in the high ALA, treatment group, while only one was in the low ALA, control group. This small number of deaths could easily have been a function of random, 'statistical clustering', particularly given that risk factors appeared lower in the high ALA treatment group.

Dr Bemelmans has actually gone on public record since the release of Hooper et al''s meta-analysis questioning the way in which her study has been used, and how her and her co-authors' positive findings have been used to demonstrate negative findings in the meta-analysis.

Just as importantly, since the omega-3 sources are vegetable oils in margarine, it is not surprising that the benefits are perhaps less pronounced given the inefficient and limited conversion by the human body of plant-derived omega-3s to key long chain fatty acids like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that are abundant in fish oils. Additionally, harmful trans fats in margarine could have been an additional confounding factor.

Cutting to the chase

Looking at all of the data in the omega-3 meta-analysis, the only area where it is possible to interpret a tendency towards very slightly negative effects, is in the case of randomised control trials (but not cohort studies) looking at the effects of omega-3 fats on cancer and stroke. However, these results could just as easily be the result of bias or confounding factors, inadequate periods of supplementation, or even the effects of contaminants in fish or fish oil capsules.

For the BMJ''s own view on the subject, it is worth referring to the Editorial published on 24 March which focuses on Hooper et al's meta-analysis. Contrary to the thrust of the meta-analysis itself, and the related media, the Editorial takes a rather positive line on omega-3s, and demonstrates concern over dwindling supplies of marine-derived omega-3s.

Citing directly from the Editorial:
"For the general public some omega 3 fat is good for health..... Adequate intake of omega 3 fats is particularly important for women of childbearing age...... We are faced with a paradox. Health recommendations advise increased consumption of oily fish and fish oils, within limits, on the grounds that intake is generally low. However, industrial fishing has depleted the world's fish stocks by some 90% since 1950, and rising fish prices reduce affordability particularly for people with low incomes. Global production trends suggest that, although fish farming is expanding rapidly, we probably do not have a sustainable supply of long chain omega 3 fats."

Additionally, there are now many Rapid Responses published in the BMJ which reinforce problems with the authors' conclusions. These can be found at: ? http://bmj.bmjjournals.com/cgi/eletters/332/7544/752.

Let you be the judge. I don't believe many people who read the full Hooper et al meta-analysis, as well as the BMJ editorial and Rapid Responses, would stop taking fish oil supplements. The problem is that only a tiny proportion of the population will do this. Many more will succumb to the negative headlines triggered by the meta-analysis and, contrary to the vast weight of evidence, they now run the risk of going against government advice to increase consumption of oily fish or fish oil supplements at recommended doses.

Those very few who interrogate the evidence considered by Hooper and colleagues might actually decide to alter their sources of omega-3 fats, shifting in the direction of high quality fish oil supplements and away from vegetarian sources of omega-3 and even oily fish, which runs the risk of contamination. This way, they can be guaranteed specific amounts of long-chain EPA and DHA, as well as being confident they are consuming products that are certified as free from contaminants.

So, despite the headlines, there is no new evidence clouding the efficacy of fish oils or long chain essential fatty acids. In fact, if the meta-analysis had included other health benefits such as immune system function, cognitive and behavioural function and joint health, the case for marine-derived omega-3s would have looked even stronger. So strong, in fact, one wonders if the media couldn't be sued by fish oil supplement manufacturers for damages. But things are rarely this simple.

We are left wondering about those negative headlines. Could there have been a motive for the negative spin?

Pharma fish oils

Just as we've seen Big Pharma control vitamin and mineral markets globally, both legally and illegally, is it not possible that this most recent skewed meta-analysis is part of a plan to discredit fish oils consumed increasingly by the masses?

When you peruse the competing interests declared in the BMJ paper, the only possible link given is that speaker fees have been paid to one of the authors by a company, Solvay, that markets a product called Omacor. Solvay is not a small marketing outfit. It is part of an international chemical and pharmaceutical group, headquartered in Brussels, which employs some 33,000 people across 50 countries. Omacor also happens to be the first prescription-only fish oil. As a licensed medicine, unlike the much more common fish oil food or dietary supplements, it can brandish extensive health and medicinal claims. Omacor, manufactured by Pronova Biocare in Norway (a private, limited company owned by Ferd Private Equity Fund), is prescribed primarily for reducing triglycerides (a major heart disease risk factor) and is positioned firmly as a stable mate with cholesterol-reducing statin drugs. In other words, the evidence for taking high quality fish oils is so convincing, drugs companies perhaps now want a slice of the action.

And the timing for the release of the meta-analysis does appear most fortuitous. In November 2004, Omacor was approved as a drug by the US Food & Drug Administration. In September 2005, Solvay Pharmaceuticals and Pronova Biocare signed a licensing agreement for exclusive distribution rights for distribution into India, Pakistan, Sri Lanka, Thailand, Vietnam, Singapore, Malaysia, China, Hong Kong and New Zealand.

Furthermore, on 1 December 2005, EPAX Sales and Production de-merged from Pronova Biocare to enable Pronova to focus exclusively on the production of prescription-only Omacor. EPAX, also based in Norway, will continue to produce concentrated omega-3 oils for the 'poor-cousin', dietary supplement industry.

Is the way actually being paved to encourage patients to elect for the prescription-only fish oil version, resplendent with all the health claims allowed under a drugs regime and banned in the food or dietary supplement sector? Even if these processes are only coincidental, and we currently have no direct evidence to suggest otherwise, the effect is the same.
The crying shame from a public health and disease prevention perspective, is that some of the most robust evidence for taking fish oils relates to their early, protective effects against heart disease. And that's why the free availability of high quality fish oil supplements is so important; people only take drugs when they become sick.

So now, those people - and there may be many - who have been unfairly frightened away from fish oil supplements might believe that they need to wait until they're sick in later life before their trusted doctors can prescribe the fish oil supplements they should have been consuming all along.

It is indeed a topsy-turvy world of lies, damn lies - and statistics.

REFERENCES
1. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA, Ebrahim SB, Davey Smith G. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. British Medical Journal, 2006; 332 (7544): 752-60.
2. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine, 2005; 142(1): 37-46.
3. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet, 2003; 361(9374): 2017-23.
4. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA, Ebrahim SB, Davey Smith G. Rapid Response in British Medical Journal: Authors reply - omega 3s and health. http://bmj.bmjjournals.com/cgi/eletters/332/7544/752#131349 [last accessed 19 April 2006].
5. Scientific Advisory Committee on Nutrition / Committee on Toxicity (UK). Advice on fish consumption: benefits and risks. Food Standards Agency / Department of Health. 2004. 204 pp.
6. Bemelmans WJ, Broer J, Feskens EJ, Smit AJ, Muskiet FA, Lefrandt JD, Bom VJ, May JF, Meyboom-de Jong B. Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean Alpha-linolenic Enriched Groningen Dietary Intervention (MARGARIN) study. American Journal of Clinical Nutrition, 2002; 75(2): 221-7.

For further information, please contact:
Alliance for Natural Health?The Atrium, Dorking,?Surrey RH4 1XA, United Kingdom?Tel: +44 (0)1252 371 275? Email: info@anhcampaign.org
This article may be copied, downloaded, printed and distributed freely as long as it is not modified in any way.
Web: www.anhcampaign.org

______________________________________________________________________________________________ 

JINI HAS MORE VERY VALUABLE INFORMATION ON HER SITE.  

                                  READ MORE KNOWLEDGEABLE ARTICLESThere are many more excellent articles available at my blog: 
http://www.listen2yourgut.com/blog
_______________________________________________________________________________________________ 

JINI'S POLICY FOR SHARING/REPUBLISHING HER ARTICLES


You are welcome to publish this newsletter, or send it on to whomever you wish,
so long as you include this copyright notice:

Copyright 2011 Jini Patel Thompson
Jini is the author of numerous books on natural healing
methods for IBS, Crohn's, diverticulitis and colitis.

http://www.listen2yourgut.com




Saturday, September 22, 2012

Safety Alert!! issued by The FDA - Drug Product for Infectious Diarrhea



FDA ISSUES SAFETY ALERT ON INTESTINOMICINA, DRUG PRODUCT MARKETED AS TREATMENT FOR INFECTIOUS DIARRHEA



WOW This stuff is just death in a bottle. The article doesn't state if the product is an OTC or prescription drug.  I would say that with the chemicals included in this cocktail of toxic shit, that it would be something the doctor must order.  IDK.  For instance, Im allergic to sulfa med and break out into a rash that's so nasty.  pennicillin and all those antibiotics with "cillin" make me rash up too.  I have no clue what Neomycin would do.
I however, have never seen this drug on any drug store shelves.  As they said it is mostly sold in international grocery stores across the US, maybe this is why.  Really, no one knows what stores this stuff may have been sold in.  Just BEWARE of the stuff in the yellow box.




September 22, 2012 (Washington, D.C.) -- The U.S. Food and Drug Administration is warning consumers not to use Intestinomicina, a drug product manufactured in El Salvador and marketed as a treatment for infectious diarrhea and acute gastrointestinal infections. Consumers who have purchased this product should immediately stop taking it and consult with a health care provider.
Intestinominica contains the prescription drug ingredient, chloramphenicol. Oral forms of chloramphenicol were formally withdrawn from the United States market in July 2012 due to the risk of serious and life threatening injuries.
Intestinomicina is labeled primarily in Spanish and lists the ingredient as “chloramfenicol palmitato,” or chloramphenicol in English, on the label. It can be found in tablet and liquid forms and is manufactured by Laboratorios Lopez. The product has been found in international grocery stores in the United States that feature South and Central American specialty foods and products.
The most serious and life-threatening injury associated with oral chloramphenicol treatment is bone marrow toxicity, which occurs when the body does not produce enough red blood cells, white blood cells, and/or platelets. Certain types of bone marrow toxicity are reversible; however, in rare circumstances it can lead to death. Patients with anemia, low white or red blood cell count, or decreased blood platelets may be at a greater risk of death or serious injury.
The product label also lists antibacterial ingredients including neomycin, an antibiotic often found in topical medications, and sulfonamides, sometimes called sulfa drugs. Neomycin and sulfa drugs have the potential to cause a variety of adverse reactions, ranging from rashes and hives, to severe and life-threatening reactions.
Intestinomicina may also interact with other medications consumers may be taking.
Health care professionals and consumers are encouraged to report any adverse events related to Intestinomicina to FDA’s MedWatch Safety Information and Adverse Event Reporting Program:
  • online at http://www.fda.gov/Medwatch/report.htm;
  • by phone at 800-FDA-1088 (800-332-1088); or,
  • by returning FDA form 3500, available on the MedWatch “Download Forms” page by mail to the address on the pre-addressed form or by fax at 800-FDA-0178. 

Link:  FDA ISSUES SAFETY ALERT ON INTESTINOMICINA, DRUG PRODUCT MARKETED AS TREATMENT FOR INFECTIOUS DIARRHEA | East County Magazine:

'via Blog this'


Wednesday, May 11, 2011

Abbott Labs -Just read 1st quarter global sales amount w/ Humira & almost puked!

Abbott's Humira is currently approved, either as a single therapy or in a combination, to treat rheumatoid and psoriatic arthritis in adults, and a type of juvenile arthritis affecting children. The drug is also approved to treat adults suffering from Crohn's disease, as well as severe chronic plaque psoriasis. Humira is a money spinner for Abbott, with first-quarter global sales improving 17.8 percent to $1.65 billion. Of this, U.S. sales grew 16.2 percent to $630 million.


In another article from RTTNews, Abbott Labs is working on getting Humira approved for Ulcerative Colitis, or UC for short.  The % of people that went into remission isn't very impressive.  It's significant, but barely.


According to the company, of the 248 patients treated with HUMIRA in the study, 16.5 percent achieved clinical remission compared to 9.3 percent on placebo at week 8. At week 52, 17.3 percent achieved clinical remission compared to 8.5 percent on placebo. These results were statistically significant compared to placebo.
HUMIRA is not approved for the treatment of UC. Abbott recently submitted applications to both the U.S. Food and Drug Administration and the European Medicines Agency seeking approval to market HUMIRA for the treatment of moderate to severe UC.

Saturday, May 7, 2011

A Short Article That Says A Lot About LDN


I like this short article because it covers the history of the drug LDN, how it started to get used for autoimmune diseases and why the FDA hasn't approved it for conditions other than drug addiction.  This article is from 2007 however, it's now 2011 and people still haven't heard about low dose naltrexone as an alternative treatment for many diseases.  I began doing research for SAFE and effective treatment for Crohn's Disease because I was on Remicade.  In my opinion, Remicade and other biologic drugs that weaken the immune system are not SAFE options.  Read the side-effect and safety indications for any of the biologics that are being used for many inflammatory diseases.  After reading this for yourself, you will understand why I consider this an unsafe treatment. Next, look up the side-effect and safety warnings for LDN/naltrexone.  
Now which one would you choose ?   

LDN - An Emerging Treatment - Article By Carl Frankel, Care2 Green Living contribution writer
If you’re one of the millions of people with auto-immune disease, there may be help for you. It’s a drug with a mouthful of a name—Low-Dosage Naltrexone, or LDN for short.
LDN is best known for its effect on multiple sclerosis. Thousands of people with MS are persuaded that it has halted the disease’s downward progression, and even reversed their symptoms. People with lupus, fibromyalgia, chronic fatigue syndrome, Crohn’s disease, and psoriasis also report benefits.
The good news doesn’t stop here. LDN is affordable—a bit over a dollar a day. Side effects——and many people don’t have them—are mild and short-term. It’s even FDA-approved, sort of. (It has “off-label” approval, meaning the FDA okayed it for a different purpose.)
The story of LDN is an intriguing saga of one man’s pioneering work, followed by a grass-roots, Internet-driven movement.
Naltrexone, without the “low-dosage” part, was developed by Dupont to treat drug addition, and approved in 1984 by the FDA for that purpose. The standard dosage was 50 milligrams, and it didn’t pan out as a treatment. Naltrexone blocks the opiate receptors in the brain. It works, in other words, by taking the fun out of taking opiates. The problem is, it takes the fun out of just about everything else, too. The result: People wouldn’t stay with the program.
Bernard Bihari, a Harvard-trained neurologist, began researching naltrexone and discovered something remarkable. When people took the drug in very low doses (3.0—4.5 milligrams instead of the standard 50 mg. dosage), it appeared to have a dramatic effect on auto-immune diseases. Bihari hypothesized that this essentially homeopathic dosage caused the body to manufacture more endorphins, which are centrally involved in supporting and regulating the immune system. He also came to believe it helped fight cancer and HIV.
Over the past 15 years or so, many thousands of people have taken LDN, to positive effect. The “anecdotal” evidence, so-called because it’s derived from stories, not studies, is overwhelmingly positive. It is also hugely persuasive, if you’re not the sort of person (your typical doctor, for instance) who requires clinical trials to be persuaded.
Where has the medical establishment been during this explosion of grassroots interest? Until recently, unmotivated and indifferent. Because the patent has expired and the drug is so inexpensive, there’s little money to be made from LDN, and therefore little reason to conduct clinical trials.
This can make it difficult to get a prescription for LDN. Because it hasn’t been clinically proven to be an effective auto-immune disease treatment, many doctors won’t prescribe it.
Recently, the medical establishment has started turning its attention to LDN, for a very simple reason: The anecdotal evidence is that overwhelming. Three national conferences on LDN have been held, and clinical trials have been launched in the United States and elsewhere. The first study to report results came out of Penn State University: “LDN therapy appears effective and safe in subjects with active Crohn’s disease.”
If you’re interested in learning more about LDN, a wealth of information is available at
www.ldninfo.org.
As for whether or not to try LDN, at the end of the day, there’s only one person who knows what’s right for you. And that’s you.
Carl Frankel is a journalist and author who has been writing about green business, green products, and integral living for the past 20 years.
More on Alternative Therapies (184 articles available)
More from Carl Frankel (12 articles available)


Read more: http://www.care2.com/greenliving/ldn-an-emerging-treatment.html#ixzz1LfORWCGV

Thursday, April 28, 2011

FDA finds more blood cancer with TNF blocker drugs *Reuters Article*


FDA finds more blood cancer with TNF blocker drugs



WASHINGTON | Thu Apr 14, 2011 4:15pm EDT

(Reuters) - U.S. health regulators have received more reports of rare blood cancer in young patients taking a class of anti-inflammatory drugs used to treat digestive disorders.

The drugs, called tumor necrosis factor (TNF) blockers, are used to treat Crohn's disease and ulcerative colitis that cause inflammation of the digestive system.

They include such widely used products as Merck & Co Inc's and Johnson & Johnson's Remicade and Simponi, Amgen Inc's Enbrel, Abbott Laboratories Inc's Humira and UCB SA's Cimzia.

The Food and Drug Administration has previously warned of an increased risk of lymphomas and other cancers associated with the use of TNF blockers in children and adolescents.

In its communication on Thursday, the FDA said the blood cancer, known as Hepatosplenic T-Cell Lymphoma or HSTCL, was reported primarily in adolescents and young adults who were taking TNF blockers, as well as other drugs such as azathioprine that also suppress the immune system and mercaptopurine, a leukemia drug.

The product labels for Remicade and Humira have been updated and the product labels for azathioprine and mercaptopurine were being updated to include warnings about HSTCL, the FDA said on its website.

The majority of the cases reported were in patients being treated for Crohn's disease or ulcerative colitis, the FDA said, but the reports also included a patient being treated for psoriasis and two patients being treated for rheumatoid arthritis.

TNF blockers suppress the immune system by blocking the activity of TNF (tumor necrosis factor), a substance in the body that can cause inflammation and lead to immune-system diseases.

Sunday, April 10, 2011

LDN Study/Trial for Active Crohn's - *link*

Low Dose Naltrexone study results - show that LDN did help Crohn's Disease sufferers. 


I'm searching to find out why this drug that is said to help people with autoimmune diseases - Crohn's being just one of the diseases, is not approved by the FDA yet for the treatment of autoimmune diseases.

There are so many positives for prescribing this drug vs all the biologics that come with the risk of some very dangerous side effects. Not to mention, naltrexone is super reasonable in price, few side-effects and is effective!

I just wanted to share my findings when searching on the FDA site for clinical trials. Let me know if you find this encouraging or helpful to you.